武彩虹,銀廣悅,錢成榮,張 龍,龔慶輝,郭 煜
(中國石油天然氣集團(tuán)公司中心醫(yī)院 檢驗(yàn)科,河北 廊坊065000)
?
可溶性E-鈣粘蛋白(SE-CAD)在系統(tǒng)性紅斑狼瘡中的臨床研究
武彩虹,銀廣悅,錢成榮,張龍,龔慶輝,郭煜
(中國石油天然氣集團(tuán)公司中心醫(yī)院 檢驗(yàn)科,河北 廊坊065000)
摘要:目的探討血清可溶性E-鈣粘蛋白(soluble E-cadherin,SE-CAD)在系統(tǒng)性紅斑狼瘡(SLE)中的表達(dá),并分析其與SLE患者一些臨床指標(biāo)的相關(guān)性。方法95例SLE患者(均為女性)作為實(shí)驗(yàn)組,35名健康體檢女性作為對(duì)照組,檢測血清SE-CAD、ESR、甘油三酯等的水平。結(jié)果SLE患者血清SE-CAD水平高于健康對(duì)照組,將SE-CAD作為因變量,患者年齡、ESR、血肌酐、GFR、膽固醇、甘油三酯、白細(xì)胞介素6(IL-6)和基質(zhì)金屬蛋白酶-3(MMP-3)作為自變量,多元回歸分析,SLE患者血清SE-CAD水平與年齡、ESR、血肌酐、膽固醇、甘油三酯、IL-6和MMP-3呈正相關(guān),其中血肌酐、年齡、ESR和甘油三酯為主要影響因素。在血肌酐﹥90 μmol/L、GFR<50 ml/min或者合并腎炎的SLE患者中血清SE-CAD水平顯著升高。結(jié)論血清SE-CAD水平可以反映SLE患者的活動(dòng)性。而且在SLE患者合并腎炎時(shí)顯著升高,提示血清SE-CAD水平可以作為診斷狼瘡性腎炎的一個(gè)標(biāo)志物。
關(guān)鍵詞:可溶性E-鈣粘蛋白;系統(tǒng)性紅斑狼瘡;ESR;肌酐;甘油三酯
(ChinJLabDiagn,2016,20:0595)
上皮鈣粘蛋白(E-CAD)是一種粘附分子,具有維持上皮細(xì)胞形態(tài)、結(jié)構(gòu)完整性的作用[1],可被基質(zhì)金屬蛋白酶(MMP)、血纖維蛋白溶酶和激肽釋放酶7等裂解,釋放出一個(gè)80 kDa的可溶性肽片段稱為SE-CAD,研究還發(fā)現(xiàn)血清SE-CAD水平不僅在腫瘤中升高[2,3],而且在炎癥性疾病中的表達(dá)也升高[4],本研究通過檢測SE-CAD、ESR、血肌酐、甘油三酯等在SLE患者血清中的表達(dá)水平,分析SE-CAD與SLE及合并腎炎患者的一些指標(biāo)的相關(guān)性。
1材料和方法
1.1研究對(duì)象95例SLE患者(均為女性),平均年齡48.7±12.7歲;35名健康女性工作人員,平均年齡45.8±11.3歲,作為對(duì)照組,所有患者在參加實(shí)驗(yàn)前都簽署了知情同意書。
1.2方法
1.2.1空腹采集檸檬酸鈉抗凝全血測定血沉,采集靜脈血分離血清測定SE-CAD、MMP-3、IL-6、血肌酐、膽固醇、低密度脂蛋白、甘油三酯,并留取24小時(shí)尿測定GFR,SE-CAD采用ELISA法檢測(試劑盒購自北京晶美生物工程有限公司,酶標(biāo)儀型號(hào)為DK1504),血清SE-CAD、MMP-3及IL-6檢測限分別為0.09 ng/ml、0.045 ng/ml和0.7 pg/ml。
1.2.2腎小球?yàn)V過率(GFR)的計(jì)算GFR(ml/min)=(140-年齡)×體重(kg)×1.04/血肌酐(μmol/L)。
1.2.3統(tǒng)計(jì)分析采用SPSS19.0分析軟件,當(dāng)變量呈正態(tài)分布時(shí)采用unpaired t檢驗(yàn)及Pearson相關(guān)性分析,當(dāng)變量不呈正態(tài)分布時(shí)采用Mann-Whitney U檢驗(yàn)及Spearman相關(guān)分析,在多元線性回歸分析中血清SE-CAD水平作為因變量,血肌酐、年齡、甘油三酯和血沉等作為自變量,P<0.05具有統(tǒng)計(jì)學(xué)意義。
2結(jié)果
2.1SLE患者血清SE-CAD水平為93.3±33.6 ng/ml,對(duì)照組SE-CAD水平為60.6±18.6 ng/ml,兩者間差異顯著(P<0.05)。SLE患者血清SE-CAD水平與年齡、ESR、血肌酐、膽固醇、甘油三酯、IL-6和MMP-3呈正相關(guān)。見表1。2.2將SE-CAD作為因變量,SLE患者年齡、ESR、血肌酐、GFR、膽固醇、甘油三酯、IL-6和MMP-3作為自變量,做多因素的回歸分析。見表2。
2.3按照血肌酐、GFR 及是否患有狼瘡腎炎,將SLE患者進(jìn)行分組,比較不同組別血清SE-CAD的水平的變化。見表3。
表1 SLE患者血清SE-CAD的水平和臨床指標(biāo)的相關(guān)性
表2 血清SE-CAD水平(因變量)與多因素(自變量)的回歸分析
注:血肌酐、年齡、ESR和甘油三酯可以作為預(yù)測血清SE-CAD水平的獨(dú)立因素
表3不同腎功能狀態(tài)下SLE患者血清SE-CAD的水平(ng/ml)χ±SD
分組血清SE-CAD血肌酐>90μmol/L120±21.2<90μmol/L72±15.1*GFR<50ml/min140±23.7>50ml/min74±15.4Δ患有狼瘡腎炎是119±20.3否79±13.9▼對(duì)照組68±11.8
注:與血肌酐>90 μmol/L組相比,*P<0.01;與GFR<50 ml/min相比組,ΔP<0.01;與患有狼瘡腎炎組相比,▼P<0.01。
3討論
國外研究報(bào)道血清SE-CAD不僅在腫瘤中的表達(dá)增加,而且在炎癥及一些自身免疫性疾病患者中的水平也升高[5]。本研究中SLE患者血清SE-CAD水平顯著高于對(duì)照組,可能由于SLE患者炎癥介質(zhì)和細(xì)胞因子的刺激,使得鈣粘蛋白與上皮細(xì)胞膜結(jié)合體分開,釋放出SE-CAD,從而使血清SE-CAD水平顯著升高[2]。
多元回歸分析SLE患者血清SE-CAD水平與年齡、ESR、血肌酐、膽固醇、甘油三酯、IL-6和MMP-3呈正相關(guān),SLE患者由于細(xì)胞因子和炎癥介質(zhì)的刺激使得MMP-3的表達(dá)增加,MMP-3可能是E-CAD脫落的強(qiáng)效酶源,使鈣粘蛋白與黏膜分開,釋放出SE-CAD[6],因此推測血清SE-CAD水平可以反映SLE患者疾病的活動(dòng)性。血清SE-CAD與IL-6和ESR 的相關(guān)性表明血清SE-CAD與SLE患者的炎癥存在一定關(guān)系,并提示IL-6可能引起E-CAD從內(nèi)皮細(xì)胞表面脫落[7]。血清SE-CAD與甘油三酯間呈正相關(guān),說明SLE患者E-CAD的脫落與脂類代謝具有一定的相關(guān)性,所以血清SE-CAD的升高可能是SLE患者發(fā)生心腦血管疾病的一個(gè)危險(xiǎn)因素[8]。
研究中當(dāng)SLE患者血肌酐>90 μmol/L、GFR<50 ml/min或者患有腎炎時(shí),血清SE-CAD水平顯著升高,P<0.001,提示血清SE-CAD可作為診斷SLE患者合并腎炎的一個(gè)生物標(biāo)志物。
參考文獻(xiàn):
[1]van Roy F,Berx G.The cell-cell adhesion molecule E-cadherin[J].Cell Mol Life Sci,2008,65:3756.
[2]De Wever O,Derycke L,Hendrix A,et al.Soluble cadherins as cancer biomarkers[J].Clin Exp Metastasis,2007,24:685.
[3]Chan AO,Chu KM,Lam SK,et al.Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer[J].J Clin Oncol,2003,21:2288.
[4]Pittard AJ,Banks RE,Galley HF,et al.Soluble E-cadherin concentrations in patients with systemic inflammatory response syndrome and multiorgan dysfunction syndrome[J].Br J Anaesth,1996,76:629.
[5]Tsai HT,Lee TH,Yang SF,et al.Markedly elevated soluble E-cadherin in plasma of patient with pelvic inflammatory disease[J].Fertil Steril,2013,99:490.
[6]Goetzl EJ,Banda MJ,Leppert D.Matrix metalloproteinases in immunity[J].J Immunol,1996,156:1.
[7]Newman W,Beall LD,Carson CW,et al.Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock[J].J Immunol,1993,150:644.
[8]Svenungsson E,Gunnarsson I,Fei GZ,et al.Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus[J].Arthritis Rheum,2003,48:2533.
Clinical Study of soluble E-cadherin in systemic lupus erythematosus
WUCai-hong,YINGuang-yue,QIANCheng-Rong,etal.
(DepartmentofClinicalLaboratory,ChinaPetroleumNaturalGasGroupCentralHospital,Langfang065000,China)
Abstract:ObjectiveTo measure serum levels of SE-CAD in systemic lupus erythematosus (SLE) and to determine associations between serum levels of SE-CAD and markers of inflammation and organ damage in female patients with SLE.MethodsSerum levels of SE-CAD were analyzed by ELISA in 95 female patients with SLE and 35 healthy women.Multiple regression analyses between SE-CAD levels and disease-related variables were performed in patients with SLE.ResultsSerum levels of SE-CAD were elevated in patients with SLE compared with levels in healthy controls.SE-CAD levels correlated positively with age、disease duration、erythrocyte sedimentation rate (ESR),s-creatinine,cholesterol,triglycerides,interleukin 6,and matrix metalloproteinase-3.In multiple regression analysis,s-creatinine、age、ESR and triglycerides remained determinants of SE-CAD.Within the patients with SLE,higher SE-CAD levels were found only in patients with renal damage(s-creatinine> 90 μmol/l,glomerular filtration rate < 50 ml/min,or renal involvement ever by SLE).ConclusionWe hypothesized that serum levels of SE-CAD reflect the disease activity of SLE.In the patients with SLE whose kidneys are affected,the SE-CAD levels were also significantly increased compared with other patients with SLE and healthy controls.Therefore SE-CAD may be used as a biomarker for kidney damage in patients with SLE.
Key words:SE-CAD;SLE;ESR;Creatinine;Triglycerides
(收稿日期:2015-06-14)
中圖分類號(hào):R593.24+1
文獻(xiàn)標(biāo)識(shí)碼:A
文章編號(hào):1007-4287(2016)04-0595-03